Why Cytokinetics Stock Was a Nearly 5% Winner Today

California-based biotech Cytokinetcs (NASDAQ: CYTK) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in a key market abroad was the catalyst for the increase, which well exceeded the slightly over 1% gain of the S&P 500 index.

A beneficial transfer

That morning, Cytokinetics announced that Sanofi has acquired the Greater China development and commercialization rights to aficamten from Chinese healthcare company Corxel. This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Details of the deal, including its price, were not disclosed.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »

Cytokinetics originally sold those rights to Corxel in 2020. The American biotech remains eligible to earn as much as $150 million in development and commercial milestone payments from the new rights holder. Additionally, it can reap royalties on future sales of the drug in Greater China. Cytokinetics said these payments range from the low-to-high-teen percentages of sales.

As if that's not enough, Cytokinetics may also be paid additional monies in connection with the execution of the Sanofi/Corxel transfer. The company did not provide further details.

Big hopes for China

In the press release trumpeting the latest aficamten arrangement, Cytokinetics waxed enthusiastic about the suitability of Sanofi as a partner. It quoted CEO Robert Blum as saying that " We now look forward to partnering with Sanofi with shared objective to leverage their cardiovascular expertise and expand the reach of aficamten to patients suffering from HCM throughout Greater China."

The company is right to be optimistic about the deal, and investors are right to be bullish on the future of its business. Aficamten has tested very well in clinical trials and, as such, has vast potential, especially in a massive market like China.

Should you invest $1,000 in Cytokinetics right now?

Before you buy stock in Cytokinetics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cytokinetics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $800,876!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of December 16, 2024

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cytokinetics. The Motley Fool has a disclosure policy.